Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin (Q38260349)

1 September 2017

1 reference

title

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin (English)

1 reference

1 September 2017

1 reference

1 reference

Takeshi Kadokura

1

1 reference

1 September 2017

Wenhui Zhang

2

1 reference

1 September 2017

Walter Krauwinkel

3

1 reference

1 September 2017

Stefanie Leeflang

4

1 reference

1 September 2017

James Keirns

5

1 reference

1 September 2017

Yuta Taniuchi

6

1 reference

1 September 2017

Ikumi Nakajo

7

1 reference

1 September 2017

Ronald Smulders

8

1 reference

1 September 2017

1 November 2014

1 reference

Clinical Pharmacokinetics

1 September 2017

1 reference

1 September 2017

53

1 reference

1 September 2017

975-988

1 reference

1 September 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-014-0180-z

1 September 2017

0 references

cites work

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Revised equations for estimated GFR from serum creatinine in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0180-Z

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

21 January 2018

1 reference

12 December 2020

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

1 reference

12 December 2020

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

1 reference

12 December 2020

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

1 reference

12 December 2020

Renal Na(+)-glucose cotransporters

1 reference

12 December 2020

[Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor]

1 reference

12 December 2020

10.1007/S40262-014-0180-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference